808 related articles for article (PubMed ID: 12707709)
1. [Hallucinations in Parkinson's disease].
Moser A; Hagenah J; Kömpf D
Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
[TBL] [Abstract][Full Text] [Related]
2. Psychosis in Parkinson's disease.
Poewe W
Mov Disord; 2003 Sep; 18 Suppl 6():S80-7. PubMed ID: 14502660
[TBL] [Abstract][Full Text] [Related]
3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
4. Clozapine prevents recurrence of psychosis in Parkinson's disease.
Factor SA; Brown D
Mov Disord; 1992; 7(2):125-31. PubMed ID: 1350059
[TBL] [Abstract][Full Text] [Related]
5. When a Parkinson's disease patient starts to hallucinate.
Poewe W
Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and therapy of Parkinson's disease].
Wittstock M; Benecke R
MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
8. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease.
Clarke C; Moore A
Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
[No Abstract] [Full Text] [Related]
10. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Zoldan J; Friedberg G; Weizman A; Melamed E
Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
[No Abstract] [Full Text] [Related]
11. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Olanow CW; Obeso JA; Stocchi F
Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
[TBL] [Abstract][Full Text] [Related]
13. [Levodopa dependency in Parkinson's disease: case report and review].
Müller U; Reuter M; Hermann W; Gertz HJ
Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
[TBL] [Abstract][Full Text] [Related]
14. Othello syndrome in patients with Parkinson's disease.
Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z
Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599
[TBL] [Abstract][Full Text] [Related]
15. Future therapies for Parkinson's disease.
Hauser RA; Lyons KE
Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
[No Abstract] [Full Text] [Related]
16. New medication recommended for Parkinson's disease.
Levenson D
Rep Med Guidel Outcomes Res; 2001 Jun; 12(13):7-9. PubMed ID: 12182172
[No Abstract] [Full Text] [Related]
17. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A
Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179
[No Abstract] [Full Text] [Related]
18. Medical hazards of the internet: gambling in Parkinson's disease.
Larner AJ
Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
[No Abstract] [Full Text] [Related]
19. Parkinson's disease: making the diagnosis, selecting drug therapies.
Scharre DW; Mahler ME
Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
Piccoli F; Riuggeri RM
J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
